Cytrx Corp., of Los Angeles, priced a public offering of about 28.6 million shares at 70 cents apiece, with investors also receiving warrants to purchase up to an aggregate of about 28.6 million shares with an exercise price of 70 cents apiece. Gross proceeds, expected to total about $20 million, will be used for working capital and general corporate purposes.